Traders Buy Agilent Technologies (A) on Weakness

Investors bought shares of Agilent Technologies Inc (NYSE:A) on weakness during trading on Monday. $61.41 million flowed into the stock on the tick-up and $24.91 million flowed out of the stock on the tick-down, for a money net flow of $36.50 million into the stock. Of all equities tracked, Agilent Technologies had the 16th highest net in-flow for the day. Agilent Technologies traded down ($0.05) for the day and closed at $71.97

A has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research note on Tuesday, October 31st. Barclays restated a “buy” rating and set a $74.00 target price on shares of Agilent Technologies in a research note on Monday, January 8th. Evercore ISI initiated coverage on shares of Agilent Technologies in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $75.00 target price on the stock. Robert W. Baird restated a “buy” rating and set a $72.00 target price on shares of Agilent Technologies in a research note on Friday, November 24th. Finally, ValuEngine cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $70.98.

The stock has a market cap of $23,250.00, a PE ratio of 32.13, a P/E/G ratio of 2.41 and a beta of 1.28. The company has a current ratio of 3.23, a quick ratio of 2.78 and a debt-to-equity ratio of 0.40.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.08. Agilent Technologies had a net margin of 4.25% and a return on equity of 17.70%. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the firm earned $0.53 EPS. analysts predict that Agilent Technologies Inc will post 2.67 EPS for the current year.

In related news, insider Patrick Kaltenbach sold 7,358 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $69.28, for a total value of $509,762.24. Following the completion of the sale, the insider now directly owns 72,862 shares of the company’s stock, valued at approximately $5,047,879.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Didier Hirsch sold 12,964 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $69.00, for a total transaction of $894,516.00. Following the completion of the sale, the chief financial officer now directly owns 184,851 shares of the company’s stock, valued at $12,754,719. The disclosure for this sale can be found here. Insiders have sold a total of 175,029 shares of company stock valued at $12,349,106 in the last ninety days.

A number of institutional investors have recently added to or reduced their stakes in the stock. Compagnie Lombard Odier SCmA purchased a new stake in Agilent Technologies in the 4th quarter worth approximately $126,000. OLD Mutual Customised Solutions Proprietary Ltd. increased its holdings in Agilent Technologies by 50.0% in the 4th quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 18,600 shares of the medical research company’s stock worth $1,246,000 after acquiring an additional 6,200 shares in the last quarter. Sterling Capital Management LLC increased its holdings in Agilent Technologies by 10.8% in the 4th quarter. Sterling Capital Management LLC now owns 100,870 shares of the medical research company’s stock worth $6,755,000 after acquiring an additional 9,822 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in Agilent Technologies in the 4th quarter worth approximately $6,669,000. Finally, Gotham Asset Management LLC increased its holdings in Agilent Technologies by 464.6% in the 4th quarter. Gotham Asset Management LLC now owns 259,354 shares of the medical research company’s stock worth $17,369,000 after acquiring an additional 213,420 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://ledgergazette.com/2018/02/19/traders-buy-agilent-technologies-a-on-weakness.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply